The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis

Olsen, 2007, Blood, 110, 1713, 10.1182/blood-2007-03-055749 Hwang, 2008, Mycosis fungoides and Sezary syndrome, Lancet, 371, 945, 10.1016/S0140-6736(08)60420-1 Criscione, 2007, Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002, Arch. Dermatol., 143, 854, 10.1001/archderm.143.7.854 Bradford, 2009, Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases, Blood, 113, 5064, 10.1182/blood-2008-10-184168 Duvic, 2001, Worldwide Study, Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results, J. Clin. Oncol., 19, 2456, 10.1200/JCO.2001.19.9.2456 Hurst, 2000, Bexarotene ligand pharmaceuticals, Curr. Opin. Investig. Drugs, 1, 514 Sherman, 1999, Central hypothyroidism associated with retinoid X receptor-selective ligands, N. Engl. J. Med., 340, 1075, 10.1056/NEJM199904083401404 Austin, 1998, Plasma triglyceride as a risk factor for cardiovascular disease, Can. J. Cardiol., 14, 14B McBride, 2007, Triglycerides and risk for coronary heart disease, JAMA, 298, 336, 10.1001/jama.298.3.336 Muccio, 1998, Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias, J. Med. Chem., 41, 1679, 10.1021/jm970635h Grubbs, 2006, Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers, Carcinogenesis, 27, 1232, 10.1093/carcin/bgi308 Lindebald, 2011, Assessment of oral toxicity and safety of 9-cis-UAB30, a potential chemopreventive agent, in rat and dog studies, Drug Chem. Toxicol., 34, 300, 10.3109/01480545.2010.536771 Kolesar, 2010, A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers, Cancer Prev. Res. (Phila), 3, 1565, 10.1158/1940-6207.CAPR-10-0149 Vedell, 2013, Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-Methyl-UAB30, and targretin (Bexarotene), Mol. Pharmacol., 83, 698, 10.1124/mol.112.082404 P.T.T.R.R.Y.M.M.J.P.G, 2014, Global molecular changes in rat livers treated with RXR agonists: a comparison using transcriptomics and proteomics, Pharmacol. Res. Perspect., 2, 1 Atigadda, 2003, Conformationally defined retinoic acid analogues. 5. Large-scale synthesis and mammary cancer chemopreventive activity for (2E,4E,6Z,8E)-8-(3',4'-dihydro-1'(2'H)-naphthalen-1'-ylidene)-3,7-dimethyl −2,4,6-octatrienoic acid (9cUAB30), J. Med. Chem., 46, 3766, 10.1021/jm030095q Grubbs, 2003, 9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers, Cancer Lett., 201, 17, 10.1016/S0304-3835(03)00461-0 Hansen, 2007, The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells, Int. J. Oncol., 30, 641 Waters, 2015, Preclinical evaluation of a novel RXR agonist for the treatment of neuroblastoma, Mol. Cancer Ther., 14, 1559, 10.1158/1535-7163.MCT-14-1103 Waters, 2016, Preclinical evaluation of UAB30 in pediatric renal and hepatic malignancies, Mol. Cancer Ther., 15, 911, 10.1158/1535-7163.MCT-15-0521 Kaltoft, 1992, Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides, In Vitro Cell. Dev. Biol., 28A, 161, 10.1007/BF02631086 McGarrity, 1983, Detection of mycoplasma infection of cell cultures by DNA fluorochrome staining, 155 Darzynkiewicz, 1997 Hsieh, 2015, Osteopontin mediates tumorigenic transformation of a preneoplastic murine cell line by suppressing anoikis: an Arg-Gly-Asp-dependent-focal adhesion kinase-caspase-8 axis, Mol. Carcinog., 54, 379, 10.1002/mc.22108 Chang, 2014, Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development, J. Dermatol. Sci., 75, 121, 10.1016/j.jdermsci.2014.05.002 Motti, 2007, Loss of p27 expression through RAS-->BRAF--> MAP kinase-dependent pathway in human thyroid carcinomas, Cell Cycle, 6, 2817, 10.4161/cc.6.22.4883 Westermann, 2007, High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status, Clin. Cancer Res., 13, 4695, 10.1158/1078-0432.CCR-06-2818 Aoki, 2011, Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1, Cancer Res., 71, 593, 10.1158/0008-5472.CAN-10-2842 Alkarain, 2004, Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer, Breast Cancer Res., 6, 13, 10.1186/bcr722 Sheaff, 1997, Cyclin E-CDK2 is a regulator of p27Kip1, Genes Dev., 11, 1464, 10.1101/gad.11.11.1464 Sutterluty, 1999, p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells, Nat. Cell Biol., 1, 207, 10.1038/12027 Carrano, 1999, SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27, Nat. Cell Biol., 1, 193, 10.1038/12013 Choi, 2015, COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth, Oncotarget, 6, 19721, 10.18632/oncotarget.3821 Lovisa, 2016, SUMOylation regulates p27Kip1 stability and localization in response to TGFbeta, J. Mol. Cell Biol., 8, 17, 10.1093/jmcb/mjv056 Tsvetkov, 1999, p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27, Curr. Biol., 9, 661, 10.1016/S0960-9822(99)80290-5 Bloom, 2003, Deregulated degradation of the cdk inhibitor p27 and malignant transformation, Semin. Cancer Biol., 13, 41, 10.1016/S1044-579X(02)00098-6 Bartek, 2001, p27 Destruction: cks1 pulls the trigger, Nat. Cell Biol., 3, E95, 10.1038/35070160 Wehmer, 2016, Recent advances in the structural biology of the 26 s proteasome, Int. J. Biochem. Cellbiol., 79, 437, 10.1016/j.biocel.2016.08.008 Frescas, 2008, Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer, Nat. Rev. Cancer, 8, 438, 10.1038/nrc2396 Fero, 1996, A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice, Cell, 85, 733, 10.1016/S0092-8674(00)81239-8 Deng, 1995, Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control, Cell, 82, 675, 10.1016/0092-8674(95)90039-X Nakayama, 2000, Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication, EMBO J., 19, 2069, 10.1093/emboj/19.9.2069 Latres, 2001, Role of the F-box protein Skp2 in lymphomagenesis, Proc. Natl. Acad. Sci. U. S. A., 98, 2515, 10.1073/pnas.041475098 Cuende, 2008, Retinoic acid downregulates Rae1 leading to APC(Cdh1) activation and neuroblastoma SH-SY5Y differentiation, Oncogene, 27, 3339, 10.1038/sj.onc.1210987 Zancai, 2005, Retinoic acid stabilizes p27Kip1 in EBV-immortalized lymphoblastoid B cell lines through enhanced proteasome-dependent degradation of the p45Skp2 and Cks1 proteins, Oncogene, 24, 2483, 10.1038/sj.onc.1208458 Nakamura, 2003, Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2, Cell Death Differ., 10, 230, 10.1038/sj.cdd.4401125 Dow, 2001, Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2, J. Biol. Chem., 276, 45945, 10.1074/jbc.M103593200 Su, 2012, All-trans retinoic acid inhibits mesangial cell proliferation by up-regulating p21Waf1/Cip1 and p27Kip1 and down-regulating Skp2, J. Nephrol., 25, 1031, 10.5301/jn.5000090 Chevrier, 2008, Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line, Int. J. Oncol., 33, 1081 Borriello, 2006, Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation, Cancer Res., 66, 4240, 10.1158/0008-5472.CAN-05-2759 Eto, 2010, Upstream molecular signaling pathways of p27(Kip1) expression: effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids, Cancer Cell Int., 10, 3, 10.1186/1475-2867-10-3 Wakino, 2001, Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators, Arterioscler. Thromb. Vasc. Biol., 21, 746, 10.1161/01.ATV.21.5.746 Balasubramanian, 2004, Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid, Carcinogenesis, 25, 1377, 10.1093/carcin/bgh122 Dahlmann, 2016, Mammalian proteasome subtypes: their diversity in structure and function, Arch. Biochem. Biophys., 591, 132, 10.1016/j.abb.2015.12.012 Jiang, 2009, Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid, Cancer. Biol. Ther., 8, 289, 10.4161/cbt.8.3.7486 Love, 2008, The novel retinoid, 9cUAB30, inhibits telomerase and induces apoptosis in HL60Cells, Transl. Oncol., 1, 148, 10.1593/tlo.08142 Whitworth, 2012, The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells, Gynecol. Oncol., 125, 226, 10.1016/j.ygyno.2011.12.425 Kim, 2015, Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells, Mol. Carcinog., 54, 1596, 10.1002/mc.22232